Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma

Genomic scar signatures associated with homologous recombination deficiency predict adverse... We investigated whether genomic scar signatures associated with homologous recombination deficiency (HRD), which include telomeric allelic imbalance (TAI), large-scale transition (LST), and loss of heterozygosity (LOH), can predict clinical outcomes in patients with ovarian clear cell carcinoma (OCCC). We enrolled patients with OCCC (n = 80) and high-grade serous carcinoma (HGSC; n = 92) subjected to primary cytoreductive surgery, most of whom received platinum-based adjuvant chemotherapy. Genomic scar signatures based on genome-wide copy number data were determined in all participants and investigated in relation to prognosis. OCCC had significantly lower genomic scar signature scores than HGSC (p < 0.001). Near-triploid OCCC spec- imens showed higher TAI and LST scores compared with diploid tumors (p < 0.001). While high scores of these genomic scar signatures were significantly associated with better clinical outcomes in patients with HGSC, the opposite was evident for OCCC. Multivariate survival analysis in patients with OCCC identified high LOH scores as the main independent adverse predictor for both cancer-specific (hazard ratio [HR] = 3.22, p = 0.005) and progression-free survival (HR = 2.54, p = 0.01). In conclusion, genomic scar signatures associated with HRD predict adverse clinical outcomes in patients with OCCC. The LOH score was identified http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Molecular Medicine Springer Journals

Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma

Download PDF
10 pages
Read Article

Loading next page...
 
/lp/springer_journal/genomic-scar-signatures-associated-with-homologous-recombination-0DQVlpCaXU
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Biomedicine; Molecular Medicine; Human Genetics; Internal Medicine
ISSN
0946-2716
eISSN
1432-1440
DOI
10.1007/s00109-018-1643-8
Publisher site
See Article on Publisher Site

Abstract

We investigated whether genomic scar signatures associated with homologous recombination deficiency (HRD), which include telomeric allelic imbalance (TAI), large-scale transition (LST), and loss of heterozygosity (LOH), can predict clinical outcomes in patients with ovarian clear cell carcinoma (OCCC). We enrolled patients with OCCC (n = 80) and high-grade serous carcinoma (HGSC; n = 92) subjected to primary cytoreductive surgery, most of whom received platinum-based adjuvant chemotherapy. Genomic scar signatures based on genome-wide copy number data were determined in all participants and investigated in relation to prognosis. OCCC had significantly lower genomic scar signature scores than HGSC (p < 0.001). Near-triploid OCCC spec- imens showed higher TAI and LST scores compared with diploid tumors (p < 0.001). While high scores of these genomic scar signatures were significantly associated with better clinical outcomes in patients with HGSC, the opposite was evident for OCCC. Multivariate survival analysis in patients with OCCC identified high LOH scores as the main independent adverse predictor for both cancer-specific (hazard ratio [HR] = 3.22, p = 0.005) and progression-free survival (HR = 2.54, p = 0.01). In conclusion, genomic scar signatures associated with HRD predict adverse clinical outcomes in patients with OCCC. The LOH score was identified

Journal

Journal of Molecular Medicine – Springer Journals

Published: May 3, 2018

References

  • Clear cell carcinoma of the ovary: a review of the literature
    Carmen, MG; Birrer, M; Schorge, JO
  • Clear-cell carcinoma of the ovary
    Fujiwara, K; Shintani, D; Nishikawa, T
  • Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers
    Chan, JK; Teoh, D; Hu, JM; Shin, JY; Osann, K; Kapp, DS
  • Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy
    Sugiyama, T; Kamura, T; Kigawa, J; Terakawa, N; Kikuchi, Y; Kita, T; Suzuki, M; Sato, I; Taguchi, K
  • Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising
    Jekimovs, C; Bolderson, E; Suraweera, A; Adams, M; O’Byrne, KJ; Richard, DJ
  • Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer
    Telli, ML; Timms, KM; Reid, J; Hennessy, B; Mills, GB; Jensen, KC; Szallasi, Z; Barry, WT; Winer, EP; Tung, NM; Isakoff, SJ; Ryan, PD; Greene-Colozzi, A; Gutin, A; Sangale, Z; Iliev, D; Neff, C; Abkevich, V; Jones, JT; Lanchbury, JS; Hartman, AR; Garber, JE; Ford, JM; Silver, DP; Richardson, AL
  • BRCA1 and BRCA2: different roles in a common pathway of genome protection
    Roy, R; Chun, J; Powell, SN
  • Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer
    Konstantinopoulos, PA; Ceccaldi, R; Shapiro, GI; D'Andrea, AD
  • Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial
    Swisher, EM; Lin, KK; Oza, AM; Scott, CL; Giordano, H; Sun, J; Konecny, GE; Coleman, RL; Tinker, AV; O'Malley, DM; Kristeleit, RS; Ma, L; Bell-McGuinn, KM; Brenton, JD; Cragun, JM; Oaknin, A; Ray-Coquard, I; Harrell, MI; Mann, E; Kaufmann, SH; Floquet, A; Leary, A; Harding, TC; Goble, S; Maloney, L; Isaacson, J; Allen, AR; Rolfe, L; Yelensky, R; Raponi, M; McNeish, IA
  • Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterization
    Lheureux, S; Lai, Z; Dougherty, BA; Runswick, S; Hodgson, DR; Timms, KM; Lanchbury, JS; Kaye, S; Gourley, C; Bowtell, D; Kohn, EC; Scott, C; Matulonis, U; Panzarella, T; Karakasis, K; Burnier, JV; Gilks, CB; O'Connor, MJ; Robertson, JD; Ledermann, J; Barrett, JC; Ho, TW; Oza, AM
  • HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
    Davies, H; Glodzik, D; Morganella, S; Yates, LR; Staaf, J; Zou, X; Ramakrishna, M; Martin, S; Boyault, S; Sieuwerts, AM; Simpson, PT; King, TA; Raine, K; Eyfjord, JE; Kong, G; Borg, Å; Birney, E; Stunnenberg, HG; Vijver, MJ; Børresen-Dale, AL; Martens, JWM; Span, PN; Lakhani, SR; Vincent-Salomon, A; Sotiriou, C; Tutt, A; Thompson, AM; van Laere, S; Richardson, AL; Viari, A; Campbell, PJ; Stratton, MR; Nik-Zainal, S
  • Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents
    Birkbak, NJ; Wang, ZC; Kim, JY; Eklund, AC; Li, Q; Tian, R; Bowman-Colin, C; Li, Y; Greene-Colozzi, A; Iglehart, JD; Tung, N; Ryan, PD; Garber, JE; Silver, DP; Szallasi, Z; Richardson, AL
  • Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation
    Popova, T; Manie, E; Rieunier, G; Caux-Moncoutier, V; Tirapo, C; Dubois, T; Delattre, O; Sigal-Zafrani, B; Bollet, M; Longy, M; Houdayer, C; Sastre-Garau, X; Vincent-Salomon, A; Stoppa-Lyonnet, D; Stern, MH
  • Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
    Abkevich, V; Timms, KM; Hennessy, BT; Potter, J; Carey, MS; Meyer, LA; Smith-McCune, K; Broaddus, R; Lu, KH; Chen, J; Tran, TV; Williams, D; Iliev, D; Jammulapati, S; FitzGerald, LM; Krivak, T; DeLoia, JA; Gutin, A; Mills, GB; Lanchbury, JS
  • Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105
    Telli, ML; Jensen, KC; Vinayak, S; Kurian, AW; Lipson, JA; Flaherty, PJ; Timms, K; Abkevich, V; Schackmann, EA; Wapnir, IL; Carlson, RW; Chang, PJ; Sparano, JA; Head, B; Goldstein, LJ; Haley, B; Dakhil, SR; Reid, JE; Hartman, AR; Manola, J; Ford, JM
  • Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs
    Marquard, AM; Eklund, AC; Joshi, T; Krzystanek, M; Favero, F; Wang, ZC; Richardson, AL; Silver, DP; Szallasi, Z; Birkbak, NJ
  • Implication of genomic characterization in synchronous endometrial and ovarian cancers of endometrioid histology
    Chao, A; Wu, RC; Jung, SM; Lee, YS; Chen, SJ; Lu, YL; Tsai, CL; Lin, CY; Tang, YH; Chen, MY; Huang, HJ; Chou, HH; Huang, KG; Chang, TC; Wang, TH; Lai, CH
  • Allele-specific copy number analysis of tumors
    Loo, P; Nordgard, SH; Lingjaerde, OC; Russnes, HG; Rye, IH; Sun, W; Weigman, VJ; Marynen, P; Zetterberg, A; Naume, B
  • Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer
    Mirza, MR; Monk, BJ; Herrstedt, J; Oza, AM; Mahner, S; Redondo, A; Fabbro, M; Ledermann, JA; Lorusso, D; Vergote, I; Ben-Baruch, NE; Marth, C; Mądry, R; Christensen, RD; Berek, JS; Dørum, A; Tinker, AV; du Bois, A; González-Martín, A; Follana, P; Benigno, B; Rosenberg, P; Gilbert, L; Rimel, BJ; Buscema, J; Balser, JP; Agarwal, S; Matulonis, UA
  • Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer
    Chao, A; Chang, TC; Lapke, N; Jung, SM; Chi, P; Chen, CH; Yang, LY; Lin, CT; Huang, HJ; Chou, HH; Liou, JD; Chen, SJ; Wang, TH; Lai, CH
  • BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer
    Sakamoto, I; Hirotsu, Y; Nakagomi, H; Ouchi, H; Ikegami, A; Teramoto, K; Amemiya, K; Mochizuki, H; Omata, M

You’re reading a free preview. Subscribe to read the entire article.

Try 2 weeks free now

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

or browse the journals available

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$499/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

Sign up
for free
Start 14 day
Free Trial